Recent News

Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma

Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?

Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma

ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma

Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma

ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma

Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity

ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma

Are Carfilzomib-Based Regimens Safe and Effective for Frail Patients With Myeloma?

ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma

ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma

Myeloma and COVID-19: Dana-Farber and Quest Diagnostics Collaborate on IMPACT Study

Trends in Myeloma by Age: Treatment and Outcome Disparities Explored

ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma

ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma

ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma

Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma

Pegfilgrastim Versus Filgrastim for Heavily Pretreated Patients With Multiple Myeloma

Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial

Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2

Salvage Therapy Under Study for Resistant Myeloma With Extramedullary Disease

SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma

Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma: ENDURANCE Trial

Older Adults With Myeloma: Second Primary Malignancy and Lenalidomide Therapy

Do Diagnostic Pathways Determine Multiple Myeloma Severity?

SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma

Chromosome 1q Abnormalities in Patients With Myeloma: Predictive of Inferior Outcomes?

Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab

Multiple Myeloma and COVID-19: Treatment Lessons Learned

FDA Brief: Priority Review for Melphalan Flufenamide Combination in Myeloma

Invasive Fungal Infections and Early Mortality in Patients With Multiple Myeloma

Bortezomib-Based Regimens Compared for Myeloma-Related Acute Kidney Injury

Daratumumab Combination Approved by FDA in Resistant Multiple Myeloma

Transplantation for Myeloma: Outcomes for Patients With Clonal Hematopoiesis

Differential Risks for Multiple Myeloma in New York City Neighborhoods

COVID-19 and Myeloma: Continuity of Care in Italian Tertiary Hospital

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma

Ongoing Phase III Trial Compares Venetoclax With Standard Therapy for Resistant Myeloma

Vaccinating Against Pneumonia in Patients With Myeloma

AACR COVID-19: Older Patients With Multiple Myeloma at Risk

Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma

AACR COVID-19: Psychosocial Distress Among Patients With Active Myeloma

FDA Advisory Panel Votes in Favor of Approving Belantamab Mafodotin in Myeloma

FDA Accepts Supplemental New Drug Application for Selinexor in Myeloma